Digestive System TRIZ Cases

Thermally stable wax compositions soften in the mouth to conform to unique dentition, resolving poor fit issues in conventional oral treatment trays.

Specific amino acid substitutions in NS1 and NS2 proteins increase viral replication efficiency, reducing required therapeutic doses for cancer treatment.

A monoclonal antibody binds specifically to amino acids 13-27 of PIVKA-II for targeted detection.

Transplanted mitochondria restore hepatocyte metabolic function and protein synthesis while reducing inflammation and fibrosis markers.

Systematic parameter changes in pH, ionic strength, and surfactant concentration stabilize high-concentration mirikizumab formulations to reduce injection pain.

A dimpled, erodible oral troche adheres to teeth or mucosa using hydrocolloid binders, maintaining localized medication release over 30 minutes.

Heating a dehydrated bowel preparation to 60°C accelerates gastric emptying, preventing nausea and vomiting while maintaining patient tolerance.

Anti-FGF19 antibodies bind the FGFR4 binding region, blocking downstream signaling and inhibiting tumor growth.

A modified-release curcumin formulation uses a gastroresistant coating and hydroxypropylmethylcellulose matrix to deliver active ingredients.

Conjugating galactose derivatives to modified oligonucleotides enables receptor-mediated endocytosis via cell surface lectins.

Heat-inactivated B. bifidum SYN-HI-001 eliminates replication risk to treat irritable bowel syndrome without viable bacteria safety hazards.

Engineered bacteria consume ammonia and produce arginine, addressing hyperammonemia and inflammation in hepatic encephalopathy.

Sweet whey protein supports normal neuronal and glial development, enhancing gastrointestinal motility and barrier function.

GC-C agonist formulations reduce inflammation without corticosteroid side effects through sustained rectal delivery.

Extrude meat slurry and flour dough at controlled shear energy to resolve the contradiction between manufacturing complexity and natural appearance resemblance.

A pharmaceutical composition combining fatty acids and antioxidants to restore intestinal permeability.

A peptide sequence targets PANX1 channels to modulate signaling pathways.

Quantifying anti-vinculin and anti-CDT antibodies distinguishes irritable bowel syndrome from inflammatory bowel disease without invasive procedures.

Anti-IL-22 antibodies block IL-22 signaling to treat steroid-resistant acute graft-versus-host disease.

Amisulpride targets dopamine D2 and serotonin 5HT2 receptors, reducing vomiting risk by 31% in high-risk surgical patients.

Salivary microbiota modulation via Bifidobacterium animalis subsp. lactis BL-11 addresses limited efficacy of behavioral treatments for Prader-Willi syndrome.

Multilayer rifaximin tablet extends gastrointestinal residence time via bioadhesive polymer, reducing administration frequency.

Anti-Claudin-1 antibodies prevent hepatocellular carcinoma recurrence by reversing the high-risk signature, avoiding invasive surgical interventions.

Ester-modified niclosamide analogues improve plasma exposure and pharmacokinetic profiles to overcome low bioavailability in oral anticancer therapy.

Combining macrogol with hyaluronic acid enhances intestinal peristalsis to maintain laxative effectiveness.

Biliary tree delivery moves stem cells to the pancreas, achieving high engraftment without organ damage.

Blocking the IL8-CXCR1 pathway with an antibody sensitizes resistant cancer stem cells to chemotherapy, reducing tumor recurrence.

Antibodies block CD48 receptor interaction to treat asthma and inflammatory bowel disease.

Coriobacteriia strains transform chenodeoxycholic acid into lithocholic acid, strengthening the intestinal barrier where conventional methods fail.

A bispecific antibody binds to 5T4 on tumor cells and CD3 on T-cells.

Oral live non-pathogenic fecal bacteria restore gut balance to resolve primary sclerosing cholangitis symptoms without ursodeoxycholic acid adverse effects.

Segmented tufted inserts deliver concentrated agents to reduce residual bacteria, addressing incomplete coverage in standard brushing routines.

A food composition containing specific carbohydrate, fiber, and omega-3 ranges improves gastrointestinal health in animals.

Inert clay minerals replace exothermic agents, absorbing liquid to concentrate blood components and stop hemorrhage without tissue damage.

A pharmaceutical composition combines natural killer cells with an anti-PD-1 antibody to target extrahepatic bile duct cancer.

Ethanol reflux and macroporous resin adsorption recover total flavonoids from discarded Carthamus tinctorius leaves, preventing resource wastage.

Alpha-2 adrenergic receptor agonists inhibit solid tumor growth by activating receptors to enhance immune cell infiltration and activity.

Combining an ACC inhibitor with a PPAR agonist reduces liver fat accumulation.

Specific polymeric compositions modify tissue elasticity and metabolic pathways to reduce fibrosis and promote regeneration.

Ethanol extraction isolates alkaloids to treat non-alcoholic fatty liver disease while preventing drug-induced hepatotoxicity.

Pyrimidine derivatives inhibit neutrophil elastase, reducing tissue destruction and inflammatory responses in chronic obstructive pulmonary disease.

Heterobifunctional compounds bridge ubiquitin ligase recruiters to target proteins, inducing selective degradation within cancer cells.

Pharmacological FAK activation promotes rapid mucosal ulcer healing, reducing surgical risks in Crohn's disease and peptic ulcers.

High-dose intravenous anti-fractalkine antibody overcomes temporary relief from standard treatments by blocking fractalkine-CX3CR1 interaction.

An anti-IL-6 receptor antibody suppresses neutrophil migration to surgical sites.